München (ots) - - Querverweis: Bildmaterial ist abrufbar unter http://www.presseportal.de/pm/122669/3836316 ...
Ariane Meynert Joins Swiss AmVac AG
Zug (ots) - As of September 1, 2007 Ariane Meynert is joining Swiss biotech company AmVac AG, Zug, as Managing Director in charge of investor and public relations.
Management graduate Meynert comes from TOMORROW FOCUS AG in Munich, a Hubert Burda Medien AG Group company where she was in charge of developing investor and public relations for several years. She previously supervised, in the same function, the successful IPO of Süss Microtec AG.
Melinda Karpati, CEO of AmVac AG, said, "I am delighted to have been able to recruit Ariane Meynert for this key position preceding AmVac AG's forthcoming IPO in the Zurich stock market's SWX segment. With her experience and her personality, she will make a successful contribution toward AmVac AG's planned stock market listing."
About AmVac AG
AmVac AG is a young biopharmaceutical company based in Switzerland that is concentrating in the high-yield pharmaceutical industry on an especially high-growth market segment. An average annual growth rate of 13% is forecast until 2010 for the vaccines market, compared with 6% for pharmaceuticals in general. AmVac products are further characterized by meeting unfulfilled therapy requirements in the fields of urology and gynecology. AmVac has to date licensed and further developed two advanced immunotherapeutic drugs with gold standard potential. Further products are in the planning stage.
ots Originaltext: AmVac AG